Uncategorized

ASH Poster 2019

Initial findings of the Phase 1 trial of PBCAR0191 Presenter: Bijal Shah, MD, Moffitt Cancer Center Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin...


Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate

-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia-...


Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

DURHAM, North Carolina, USA, July 18, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary...


Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial

DURHAM, North Carolina, USA, Nov 12, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...


Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

–Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia-...


Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...


Precision BioSciences to Present at Upcoming Industry and Investor Conferences

DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering,...


Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer

DURHAM, North Carolina, USA, Sept. 23, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary...


Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress

DURHAM, N.C., Aug. 14, 2019 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its...


Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States

DURHAM, North Carolina, USA, July 18, 2019 – – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary...


Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress

DURHAM, N.C. and BRISBANE, Australia, July 10, 2019 – Elo Life Systems Inc. (“Elo”), a wholly owned subsidiary of Precision BioSciences, Inc. (Nasdaq: DTIL) announced today that Mario G....


Precision BioSciences Appoints Dario Scimeca as General Counsel

DURHAM, North Carolina, USA, June 12, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS®...


Precision BioSciences to Present at Upcoming Investor Conferences

DURHAM, North Carolina, USA, May 29, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary...


Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer

DURHAM, North Carolina, USA, May 14, 2019 – Precision BioSciences (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome...


Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

DURHAM, North Carolina, May 09, 2019 – Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary...